Vaccine slows breast cancer

An experimental breast cancer vaccine has been shown to slow progression of the disease in human patients.

Of 14 women with advanced breast cancer who received the vaccine, half showed no sign of tumour growth one year after treatment.

The vaccine had an effect even in those with immune systems weakened by the disease and chemotherapy.

Scientists now plan to follow the small pilot trial with a larger study of newly diagnosed patients who should have stronger immune systems.

Professor William Gillanders, from Washington University School of Medicine, said: “Despite the weakened immune systems in these patients, we did observe a biologic response to the vaccine while analysing immune cells in their blood samples.

“That’s very encouraging. We also saw preliminary evidence of improved outcome, with modestly longer progression-free survival.”

The vaccine primes the immune system to target a protein called mammaglobin-A which is found almost exclusively in breast tissue. Breast cancer tumours produce it at abnormally high levels.

“Being able to target mammaglobin is exciting because it is expressed broadly in up to 80% of breast cancers, but not at meaningful levels in other tissues,” said Prof Gillanders.

The vaccine would not be effective in the small number of breast cancer patients whose tumours do not generate mammaglobin-A.

The trial was chiefly designed to assess the vaccine’s safety and side effects, but the scientists also obtained preliminary data on its effectiveness. The 14 treated patients all had metastatic, or spreading, breast cancer and tested positive for mammaglobin-A.